Kumho HT Delivers 4 Million COVID-19 Rapid Test Kits

[Asia Economy Reporter Lee Gwan-joo] Kumho HT announced on the 3rd that it has signed a contract to supply COVID-19 rapid antigen self-test kits to a domestic medical device distribution company. Approximately 4 million kits will be supplied and used overseas.

Kumho HT obtained export approval for COVID-19 rapid diagnostic test kits (RDT) from the Ministry of Food and Drug Safety in December last year.

A company official stated, “After completing the merger with Dinona, we have focused on research of immune-oncology drugs such as antigen therapeutics DNP002 and DNP007. However, due to the recent surge in COVID-19 cases caused by the Omicron variant, public quarantine measures have been strengthened and demand for diagnostic products has increased, so we have additionally proceeded with the production and supply of rapid antigen test kits.”

Kumho HT recently completed a merger with the antibody therapeutic development bio company Dinona. After the merger, it became the largest shareholder of Hwail Pharmaceuticals, a KOSDAQ-registered pharmaceutical manufacturing company. By establishing its own bio business division and securing a pharmaceutical company as a subsidiary, it has completed vertical integration.